Recent Updates
Recently added Catalysts

vormatrogine

Phase 3

Epilepsy, Tonic-Clonic | Small molecule | Neurology |Praxis Precision Medicines, Inc.|Last Updated: Dec 17, 2025

Success Probability
Subscribe to view
Market & Valuation
Subscribe to view
Trial Design
UNCONTROLLED
Total Trials1
Total Enrollment700
FDA Designations
No designations recorded
Clinical trial landscape

vormatrogine · 1 trial · 3 indications

Phase 3 1
NCT07287163Clinical Trial of Vormatrigine in Adult Patients With EpilepsyEpilepsy, Tonic-Clonic
ENROLLING BY_INVITATION700 Analytics
PHASE3ENROLLING BY_INVITATION
Clinical Trial of Vormatrigine in Adult Patients With Epilepsy
Epilepsy, Tonic-Clonic
NCT07287163700
Unlock trial analytics
Study Endpoints
Primary Endpoints
To assess the safety and tolerability of vormatrigine in adults with focal or primary generalized tonic-clonic seizures
Up to 2 years

Incidence and severity of TEAEs including discontinuation of study drug due to TEAEs

Unlock Study Endpoints
Study Design & Arms
AllocationNA
MaskingNONE
ModelSINGLE_GROUP
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
Open-label 30 mg/day vormatrogine for up to 2 yearsEXPERIMENTALParticipants who meet all eligibility criteria will receive 30 mg of vormatrogine for up to 2 years.
Interventions
NameTypeDescription
vormatrogineDRUGOnce daily oral
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years to 85 Years
SexALL
Healthy VolunteersNo
Study Sites20

Inclusion Criteria: * Participant who completed an eligible clinical trial (unless agreed by the sponsor medical monitor), including PRAX-628-212, PRAX-628-321 or other vormatrigine trials, or participant who has received vormatrigine outside of an eligible clinical trial (such as an expanded acces...

Countries:United StatesGermanyItalyPolandSpain
Unlock Eligibility Criteria
Recent Changes (Last 90 Days)
LOWMay 26, 2026NCT07287163primaryCompletionDate: changed
LOWMay 24, 2026NCT07287163studyFirstPostDate: changed